Scott Coleman
Corporate Officer/Principal chez XILIO THERAPEUTICS, INC.
Postes actifs de Scott Coleman
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| XILIO THERAPEUTICS, INC. | Corporate Officer/Principal | 01/06/2022 | - |
Historique de carrière de Scott Coleman
Anciens postes connus de Scott Coleman
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ACCELERON PHARMA INC. | Corporate Officer/Principal | - | - |
Formation de Scott Coleman
| North Carolina State University | Doctorate Degree |
| Northeastern University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| XILIO THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis on June 13, 2003 and is headquartered in Rahway, NJ. | Health Technology |
- Bourse
- Insiders
- Scott Coleman
- Expérience
